Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Continued pipeline progression of the existing clinical-stage development programmes of FG001 in high-grade glioma and oral head and neck cancer. We expect topline results in H1 2027 from the Phase II (part 2) trials for FG001 in high-grade glioma (CT-006) and oral head and neck cancer (CT-005). Also, we believe there is a high likelihood of FluoGuide announcing another partnership within the next 12 months.
Long term
6+ YEARS
The long-term value creation depends on achieving regulatory approvals of FG001 in high-grade glioma and oral head and neck cancer and successfully executing on the go-to market strategy. In addition to high-grade glioma and oral head and neck cancer, we believe FluoGuide could initiate Phase II trials across adjacent oncology indications, aiming at expanding the label.
Regulatory delays.
Cost overruns.
Dependency on partnerships.
Price
Fair range high value
Fair range low value
Our fair value range is based on risk-adjusted sales for FG001 in high-grade glioma, low-grade glioma, meningioma and oral head and neck cancer. The range is driven by the H1 2027 topline readouts of CT-006 (HGG) and CT-005 (HNC): the upper end assumes positive data and higher approval probabilities, the lower end weaker data and delays.
Our valuation is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.3 equity beta and a 5% liquidity premium).
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB